Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus–Infected Patients With CD4 T-Cell Counts  | Zendy

Somnuek Sungkanuparph | Zendy; Chutchaiwat Savetamornkul | Zendy; Warisara Pattanapongpaiboon | Zendy

Open Access

Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus–Infected Patients With CD4 T-Cell Counts <100 Cells/µL and Receiving Antiretroviral Therapy

Author(s) -

Somnuek Sungkanuparph,

Chutchaiwat Savetamornkul,

Warisara Pattanapongpaiboon

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix036

Subject(s) - medicine , cryptococcosis , fluconazole , virology , antiretroviral therapy , sida , viral disease , human immunodeficiency virus (hiv) , immunopathology , immunology , opportunistic infection , mycosis , aids related opportunistic infections , secondary prophylaxis , antifungal , viral load , dermatology

A prospective observational cohort study was conducted in 302 human immunodeficiency virus-infected patients who had a CD4 T-cell count <100 cells/µL and negative serum cryptococcal antigen initiating antiretroviral therapy in a resource-limited setting. During 2-year follow-up, there were no differences of survival rates and occurrences of newly diagnosed cryptococcosis between patients with and without fluconazole for primary prophylaxis of cryptococcosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research